These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1716021)

  • 21. Value of prostate-specific antigen measurements in predicting lymph node involvement in prostatic cancer.
    Arai Y; Yoshiki T; Yamabe H; Yoshida O
    Urol Int; 1990; 45(6):356-60. PubMed ID: 1705062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.
    Epstein JI; Walsh PC; Carmichael M; Brendler CB
    JAMA; 1994 Feb; 271(5):368-74. PubMed ID: 7506797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between systematic biopsies and histological features of 222 radical prostatectomy specimens: lack of prediction of tumor significance for men with nonpalpable prostate cancer.
    Noguchi M; Stamey TA; McNeal JE; Yemoto CM
    J Urol; 2001 Jul; 166(1):104-9; discussion 109-10. PubMed ID: 11435833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion.
    Quinn DI; Henshall SM; Brenner PC; Kooner R; Golovsky D; O'Neill GF; Turner JJ; Delprado W; Grygiel JJ; Sutherland RL; Stricker PD
    Cancer; 2003 Apr; 97(8):1884-93. PubMed ID: 12673714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Percent of cancer in the biopsy set predicts pathological findings after prostatectomy.
    Grossklaus DJ; Coffey CS; Shappell SB; Jack GS; Chang SS; Cookson MS
    J Urol; 2002 May; 167(5):2032-5; discussion 2036. PubMed ID: 11956432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng./ml.
    Zlotta AR; Djavan B; Petein M; Susani M; Marberger M; Schulman CC
    J Urol; 1998 Dec; 160(6 Pt 1):2089-95. PubMed ID: 9817330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer.
    Kupelian P; Katcher J; Levin H; Zippe C; Klein E
    Urology; 1996 Aug; 48(2):249-60. PubMed ID: 8753737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia.
    Partin AW; Carter HB; Chan DW; Epstein JI; Oesterling JE; Rock RC; Weber JP; Walsh PC
    J Urol; 1990 Apr; 143(4):747-52. PubMed ID: 1690309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of the complexed-to-total prostate-specific antigen ratio in predicting the final pathological stage of clinically localized prostate cancer.
    Martínez M; Navarro S; Medina P; Villavicencio H; Rioja L; Solsona E; Estellés A; Aznar J; Jiménez-Cruz JF; España F
    Eur Urol; 2003 Jun; 43(6):609-14. PubMed ID: 12767360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preoperative serum levels of early prostate cancer antigen (EPCA) predict prostate cancer progression in patients undergoing radical prostatectomy.
    Zhao Z; Ma W; Zeng G; Qi D; Ou L; Liang Y
    Prostate; 2012 Feb; 72(3):270-9. PubMed ID: 21630293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear deoxyribonucleic acid ploidy and serum prostate specific antigen in operable prostatic adenocarcinoma.
    Nativ O; Myers RP; Farrow GM; Therneau TM; Zincke H; Lieber MM
    J Urol; 1990 Aug; 144(2 Pt 1):303-6. PubMed ID: 1695690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate.
    Seaman EK; Whang IS; Cooner W; Olsson CA; Benson MC
    Urology; 1994 May; 43(5):645-8. PubMed ID: 7513107
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of preoperative plasma endoglin for prediction of lymph node metastasis in patients with clinically localized prostate cancer.
    Karam JA; Svatek RS; Karakiewicz PI; Gallina A; Roehrborn CG; Slawin KM; Shariat SF
    Clin Cancer Res; 2008 Mar; 14(5):1418-22. PubMed ID: 18316564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
    Noldus J; Stamey TA
    J Urol; 1996 Jan; 155(1):232-7. PubMed ID: 7490842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications.
    Shinohara K; Wolf JS; Narayan P; Carroll PR
    J Urol; 1994 Jul; 152(1):120-3. PubMed ID: 7515447
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
    Kupelian PA; Katcher J; Levin HS; Klein EA
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(5):1043-52. PubMed ID: 9169811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of potentially insignificant prostate cancer in men undergoing radical prostatectomy for clinically organ-confined disease.
    Miyake H; Sakai I; Harada K; Hara I; Eto H
    Int J Urol; 2005 Mar; 12(3):270-4. PubMed ID: 15828954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of post-radical prostatectomy pathological outcome for stage T1c prostate cancer with percent free prostate specific antigen: a prospective multicenter clinical trial.
    Southwick PC; Catalona WJ; Partin AW; Slawin KM; Brawer MK; Flanigan RC; Patel A; Richie JP; Walsh PC; Scardino PT; Lange PH; Gasior GH; Parson RE; Loveland KG
    J Urol; 1999 Oct; 162(4):1346-51. PubMed ID: 10492194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.